```
                                                        ENTRY     SESSION
FULL ESTIMATED COST                                     561.62     561.83

FILE 'CAPLUS' ENTERED AT 09:08:01 ON 22 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 22 Aug 2006  VOL 145 ISS 9
FILE LAST UPDATED: 21 Aug 2006  (20060821/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l20
L21          4 L20

=> d bib abs hitstr 1-4

L21  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
AN   2005:1042214  CAPLUS
DN   143:326204
TI   Benzyllactam derivatives as modulators of serotonin 1 receptors, their
     preparation, pharmaceutical compositions, and use in therapy
IN   Brodney, Michael Aaron; Caron, Stephane; Helal, Christopher J.; Raggon,
     Jeffrey W.; Tao, Yong; Do, Nga M.
PA   Pfizer Products Inc., USA
SO   PCT Int. Appl., 67 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 2005090300        A1    20050929    WO 2005-IB583          20050307
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     NL 1028558          A1    20050920    NL 2005-1028558        20050316
     US 2005245521       A1    20051103    US 2005-83188          20050317
PRAI US 2004-553808P     P     20040317
OS   MARPAT 143:326204
GI
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to benzyl(idene)-lactam derivs. I, which are modulators of serotonin 1 (5-HT1) receptors. In compds. I, n is 1-3; R1 is substituted piperazin-1-yl or piperidin-4-yl; X is H, Cl, F, Br, I, cyano, C1-6 alkyl, OH, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, carboxy, or aminocarbonyl; R3 is -(CH2)g-B, where g is 0-3 and B is H, (un)substituted Ph, (un)substituted naphthyl, or a 5- or 6-membered (un)substituted heteroaryl ring containing one to four heteroatoms, selected from O, N, and S; or corresponding benzylidene derivs., pharmaceutically acceptable salts or optical isomers thereof. The invention also relates to the preparation of I, pharmaceutical compns. containing I with a pharmaceutically acceptable carrier, as well as to the use of the compds. for treating or preventing depression, anxiety, obsessive compulsive disorder (OCD) and other disorders for which a 5-HT1 agonist or antagonist is indicated. Regioselective substitution of 2,5-difluorobenzaldehyde with 1-methylpiperazine followed by condensation with N-acetylpyrrolidin-2-one, hydrolysis, and hydrogenation resulted in the formation of pyrrolidinone II. Compound II was coupled to 2-(4-bromophenyl)-propan-2-ol, prepared by addition of methylmagnesium bromide to Me 4-bromobenzoate, to give benzyllactam III. All tested compds. had IC50 values of 1000 nM or less. The compds. of the invention include selective antagonists, inverse agonists and partial agonists of 5-HT1 receptors (no specific data).

IT 865204-44-0P, 3-[2-(4-Methylpiperazin-1-yl)benzyl]-1-[4-(2-oxopyrrolidin-1-ylmethyl)phenyl]piperidin-2-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzyllactam derivs. as modulators of serotonin 1 receptors)

RN 865204-44-0 CAPLUS

CN 2-Piperidinone, 3-[[2-(4-methyl-1-piperazinyl)phenyl]methyl]-1-[4-[(2-oxo-1-pyrrolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:772650 CAPLUS

DN 141:295862
TI A preparation of cyclohexyl and piperidinyl derivatives, useful as melanocortin-4 receptor modulators
IN Soeberdt, Michael; Weyermann, Philipp; Von Sprecher, Andreas
PA Myocontract Ltd., Switz.
SO Eur. Pat. Appl., 95 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1460069	A1	20040922	EP 2003-6255	20030320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	AU 2004222097	A1	20040930	AU 2004-222097	20040319
	CA 2519372	AA	20040930	CA 2004-2519372	20040319
	WO 2004083198	A1	20040930	WO 2004-EP2909	20040319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1606278	A1	20051221	EP 2004-721881	20040319
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRAI	EP 2003-6255	A	20030320		
	WO 2004-EP2909	A	20040319		

OS MARPAT 141:295862
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to novel substituted cyclohexyl and piperidinyl derivs. of formula I [wherein: X is N or CH; Y is (CH2)0-2; Z is (CH2)0-2; R1 is H, OH, CN, NO2, alkyl, alkoxy, or -D-C(O)-heteroaryl, etc; R2 is derivative of pyridine, piperidine, or isoindole, etc.; R3 is -D-(hetero)aryl; R4 is H or bond; D is a bond or alkylene], useful as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Representative compds. of the invention were tested in functional assay and found to activate the melanocortin-4-receptor with EC50 values less than 1 μM. For instance, cyclohexane derivative II•HCl (R5 = H) was prepared via amidation of isoquinolinecarboxylic acid derivative III by the obtained amine IV•HCl and subsequent N-cleavage of the obtained amide II (R5 = BOC) (example 1, no yield data).

IT 760972-65-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclohexyl and piperidinyl derivs., useful as melanocortin-4 receptor modulators)

RN 760972-65-4 CAPLUS
CN 3-Isoquinolinecarboxamide, N-[(1S)-1-[(4-chlorophenyl)methyl]-2-[1-[2-[(2-oxo-1-pyrrolidinyl)methyl]phenyl]-4-piperidinylidene]ethyl]-1,2,3,4-tetrahydro-, monohydrochloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 760972-73-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclohexyl and piperidinyl derivs., useful as melanocortin-4 receptor modulators)
RN 760972-73-4 CAPLUS
CN 2(1H)-Isoquinolinecarboxylic acid, 3-[[[(1S)-1-[(4-chlorophenyl)methyl]-2-[1-[2-[(2-oxo-1-pyrrolidinyl)methyl]phenyl]-4-piperidinylidene]ethyl]amino]carbonyl]-3,4-dihydro-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L21 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:372868 CAPLUS
DN 140:375080
TI Preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor inhibitors

IN Apodaca, Richard L.; Dvorak, Curt A.; Shah, Chandravadan R.; Xiao, Wei
PA USA
SO U.S. Pat. Appl. Publ., 47 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004087573	A1	20040506	US 2003-692080	20031023
PRAI US 2002-420494P	P	20021023		

OS MARPAT 140:375080
GI



I



II

AB Substituted phenylpiperidines and phenylpyrrolidines of formula I [L = bond, alkylene, etc.; R1,R2 = H, alkyl, cycloalkyl, heterocyclyl, etc.; R1R2 = alkylene, heteroalkylene, etc.; R3-R5 = H, halo, nitro, CF3, Me, alkoxy; R6 = alkyl, CF3; X = (CH2)p; Y = (CH2)q; p = 0-2; q = 1-2; m = 0-3], compns. containing them, and methods of making and using them to treat histamine-mediated conditions are described. Thus, II was prepared from 1-(4-pyrrolidinomethylphenyl)piperidin-4-carbaldehyde and cyclohexylamine. The Ki value of II was 0.9 nM in {3H}-N-methylhistamine binding assay.

IT 683772-25-0P 683772-28-3P 683772-29-4P
683772-30-7P 683772-31-8P 683772-32-9P
683772-33-0P 683772-34-1P 683772-35-2P
683772-36-3P 683772-37-4P 683772-39-6P
683772-40-9P 683772-41-0P 683772-42-1P
683772-44-3P 683772-46-5P 683772-52-3P
683772-57-8P 683772-59-0P 683772-69-2P
683772-70-5P 683772-71-6P 683772-72-7P
683772-73-8P 683772-74-9P 683772-75-0P
683772-76-1P 683772-77-2P 683772-78-3P
683772-79-4P 683772-81-8P 683772-82-9P
683772-83-0P 683775-76-0P
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor inhibitors)

RN 683772-25-0 CAPLUS
CN Azacyclotridecane, 1-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-28-3 CAPLUS
CN Piperazine, 1-methyl-4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683772-29-4 CAPLUS
CN 4-Piperidinol, 1-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-30-7 CAPLUS
CN Thiomorpholine, 4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-31-8 CAPLUS
CN Piperidine, 4-(1-piperidinylmethyl)-1-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 683772-32-9 CAPLUS
CN Morpholine, 4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-33-0 CAPLUS
CN Thiomorpholine, 4-[[3-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-34-1 CAPLUS
CN Morpholine, 4-[[3-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-35-2 CAPLUS
CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[3-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 683772-36-3 CAPLUS
CN Piperidine, 1-[3-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-37-4 CAPLUS
CN Azacyclotridecane, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-39-6 CAPLUS
CN 4-Piperidinol, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683772-40-9 CAPLUS
CN Piperazine, 1-methyl-4-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683772-41-0 CAPLUS
CN Thiomorpholine, 4-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-42-1 CAPLUS
CN Morpholine, 4-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]-
(9CI) (CA INDEX NAME)



RN 683772-44-3 CAPLUS
CN Morpholine, 4-[[2-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]-
(9CI) (CA INDEX NAME)



RN 683772-46-5 CAPLUS
CN Piperidine, 1-[4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-52-3 CAPLUS
CN Morpholine, 4-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-57-8 CAPLUS
CN 2-Pyridinamine, N-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-59-0 CAPLUS
CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 683772-69-2 CAPLUS
CN Piperidine, 1-[4-(1-piperidinylmethyl)-2-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-70-5 CAPLUS
CN Piperidine, 1-[2-nitro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-71-6 CAPLUS
CN Morpholine, 4-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-72-7 CAPLUS
CN 4-Piperidinol, 1-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683772-73-8 CAPLUS
CN Piperidine, 1-[4-(1-piperidinylmethyl)-3-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-74-9 CAPLUS
CN Piperazine, 1-(1-methylethyl)-4-[[3-methyl-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 683772-75-0 CAPLUS
CN Piperidine, 1-[2-methyl-4-(1-pyrrolidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-76-1 CAPLUS
CN Piperidine, 1-[2-methyl-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-77-2 CAPLUS
CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 683772-78-3 CAPLUS
CN Piperidine, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-2-

(trifluoromethyl)phenyl]methyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683772-79-4 CAPLUS
CN Piperidine, 1-[2-fluoro-4-[(4-phenyl-1-piperidinyl)methyl]phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683772-81-8 CAPLUS
CN Piperidine, 1-[2-fluoro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-82-9 CAPLUS
CN 1,4,7,10-Tetraoxa-13-azacyclopentadecane, 13-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-83-0 CAPLUS
CN 4-Piperidinemethanol, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683775-76-0 CAPLUS
CN Methanesulfonic acid, trifluoro-, compd. with 13-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-2-(trifluoromethyl)phenyl]methyl]-1,4,7,10-tetraoxa-13-azacyclopentadecane (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 683772-82-9
CMF C28 H44 F3 N3 O4



CM 2

CRN 1493-13-6
CMF C H F3 O3 S



L21 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:368927 CAPLUS
DN 140:391199
TI Preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor modulators
IN Apodaca, Richard L.; Dvorak, Curt A.; Shah, Chandravadan R.; Xiao, Wei
PA Janssen Pharmaceutica, N.V., Belg.
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004037257	A1	20040506	WO 2003-US33809	20031023
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2504272	AA	20040506	CA 2003-2504272	20031023
	AU 2003287206	A1	20040513	AU 2003-287206	20031023
	EP 1556046	A1	20050727	EP 2003-781386	20031023
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006505590	T2	20060216	JP 2004-547134	20031023
PRAI	US 2002-420494P	P	20021023		
	WO 2003-US33809	W	20031023		

OS MARPAT 140:391199
GI



I



II

AB The title compds. [I; L = a bond, alkylene, alkenylene, etc.; p = 0-2; q = 1-2 (provided that 2≤p+q≤4); R1, R2 = H, alkyl, Ph, etc.; or NR1R2 = (un)substituted saturated 3-13 membered heterocyclyl; one R3-R5 = G and the other two = H, F, Cl, Br, NO2, CF3, Me, alkoxy; G = L2Q; L2 = (CH2)n; n = 1-7; Q = NR8R9 (R8, R9 = H, alkyl, Ph, etc.; or NR8R9 = (un)substituted saturated 3-15 membered heterocyclyl); R6 = H, alkyl; CF3; m = 0-3], useful for treating histamine-mediated conditions, were prepared Thus, 1-[2-(morpholin-4-ylmethyl)phenyl]piperidine-4-carbaldehyde with piperidine in the presence of NaBH(OAc)3 in DCE afforded II which showed Ki of 4500 nM against H3 receptor binding. The pharmaceutical compns. comprising the compds. I are claimed.

IT 683772-25-0P 683772-28-3P 683772-29-4P
683772-30-7P 683772-31-8P 683772-32-9P
683772-33-0P 683772-34-1P 683772-35-2P
683772-36-3P 683772-37-4P 683772-39-6P
683772-40-9P 683772-41-0P 683772-42-1P
683772-44-3P 683772-46-5P 683772-52-3P
683772-57-8P 683772-59-0P 683772-69-2P
683772-70-5P 683772-71-6P 683772-72-7P
683772-73-8P 683772-74-9P 683772-75-0P
683772-76-1P 683772-77-2P 683772-78-3P
683772-79-4P 683772-81-8P 683772-83-0P
683775-76-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylpiperidines and phenylpyrrolidines as histamine H3 receptor modulators)

RN 683772-25-0 CAPLUS

CN Azacyclotridecane, 1-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-28-3 CAPLUS
CN Piperazine, 1-methyl-4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683772-29-4 CAPLUS
CN 4-Piperidinol, 1-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-30-7 CAPLUS
CN Thiomorpholine, 4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-31-8 CAPLUS
CN Piperidine, 4-(1-piperidinylmethyl)-1-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 683772-32-9 CAPLUS
CN Morpholine, 4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-33-0 CAPLUS
CN Thiomorpholine, 4-[[3-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-34-1 CAPLUS
CN Morpholine, 4-[[3-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-35-2 CAPLUS
CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[3-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 683772-36-3 CAPLUS
CN Piperidine, 1-[3-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-37-4 CAPLUS
CN Azacyclotridecane, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-39-6 CAPLUS
CN 4-Piperidinol, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683772-40-9 CAPLUS
CN Piperazine, 1-methyl-4-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683772-41-0 CAPLUS
CN Thiomorpholine, 4-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-42-1 CAPLUS
CN Morpholine, 4-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]-
(9CI) (CA INDEX NAME)



RN 683772-44-3 CAPLUS
CN Morpholine, 4-[[2-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]-
(9CI) (CA INDEX NAME)



RN 683772-46-5 CAPLUS
CN Piperidine, 1-[4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-52-3 CAPLUS
CN Morpholine, 4-[[4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-57-8 CAPLUS
CN 2-Pyridinamine, N-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-59-0 CAPLUS
CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 683772-69-2 CAPLUS
CN Piperidine, 1-[4-(1-piperidinylmethyl)-2-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-70-5 CAPLUS
CN Piperidine, 1-[2-nitro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-71-6 CAPLUS
CN Morpholine, 4-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 683772-72-7 CAPLUS
CN 4-Piperidinol, 1-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683772-73-8 CAPLUS
CN Piperidine, 1-[4-(1-piperidinylmethyl)-3-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-74-9 CAPLUS
CN Piperazine, 1-(1-methylethyl)-4-[[3-methyl-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 683772-75-0 CAPLUS
CN Piperidine, 1-[2-methyl-4-(1-pyrrolidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-76-1 CAPLUS
CN Piperidine, 1-[2-methyl-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-77-2 CAPLUS
CN Piperidine, 4-(1-pyrrolidinylmethyl)-1-[4-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 683772-78-3 CAPLUS
CN Piperidine, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-2-

(trifluoromethyl)phenyl]methyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683772-79-4 CAPLUS
CN Piperidine, 1-[2-fluoro-4-[(4-phenyl-1-piperidinyl)methyl]phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683772-81-8 CAPLUS
CN Piperidine, 1-[2-fluoro-4-(1-piperidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)



RN 683772-83-0 CAPLUS
CN 4-Piperidinemethanol, 1-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 683775-76-0 CAPLUS
CN Methanesulfonic acid, trifluoro-, compd. with 13-[[4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]-2-(trifluoromethyl)phenyl]methyl]-1,4,7,10-tetraoxa-13-azacyclopentadecane (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 683772-82-9
CMF C28 H44 F3 N3 O4



CM 2

CRN 1493-13-6
CMF C H F3 O3 S



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
L1                STR
L2              0 SEA FILE=REGISTRY SSS FUL L1

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
REP G1=(0-2) CH
VAR G2=8/9/10
VAR G3=4/5/1
NODE ATTRIBUTES:
NSPEC   IS R       AT  18
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   3   6
NUMBER OF NODES IS  19

STEREO ATTRIBUTES: NONE
```

```
=> d l7
L7 HAS NO ANSWERS
L7                STR
```




```
REP G1=(0-5) C
VAR G2=8/9/10
VAR G3=2/1/19/20/5
NODE ATTRIBUTES:
NSPEC   IS R       AT  18
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   6   3
NUMBER OF NODES IS  21

STEREO ATTRIBUTES: NONE


=> s l7 ful
FULL SEARCH INITIATED 11:37:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   834435 TO ITERATE

100.0% PROCESSED   834435 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.10

L9             0 SEA SSS FUL L7
```

```
=> d l12
L12 HAS NO ANSWERS
L12              STR
```




```
VAR G2=8/9/10
NODE ATTRIBUTES:
NSPEC   IS R       AT  18
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   6   3
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE


=> s l12 ful
FULL SEARCH INITIATED 09:01:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   825173 TO ITERATE

100.0% PROCESSED   825173 ITERATIONS                                  518 ANSWERS
SEARCH TIME: 00.00.10

L14          518 SEA SSS FUL L12

=> s l14 and piperidin?
         976018 PIPERIDIN?
L15         472 L14 AND PIPERIDIN?

=> d scan

L15  472 ANSWERS   REGISTRY  COPYRIGHT 2006 ACS on STN
IN   Piperazine, 1-[4-(4-methyl-1-piperidinyl)-3-nitrobenzoyl]-4-
     (phenylsulfonyl)- (9CI)
MF   C23 H28 N4 O5 S
```



```
=> d l16
L16 HAS NO ANSWERS
L16                STR
```




```
REP G1=(1-8) CH
VAR G2=8/9/10
NODE ATTRIBUTES:
NSPEC   IS R       AT  18
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   6   3
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE


=> search l16
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
ENTER SUBSET L# OR (END):l15
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 09:03:00 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -      472 TO ITERATE

100.0% PROCESSED      472 ITERATIONS                          114 ANSWERS
SEARCH TIME: 00.00.01

L17         114 SEA SUB=L15 SSS FUL L16
```

```
=> s l17 and pyrrolidin?
        582391 PYRROLIDIN?
L20         39 L17 AND PYRROLIDIN?

=> d scan

L20  39 ANSWERS   REGISTRY  COPYRIGHT 2006 ACS on STN
IN   Piperidine, 1-[2-nitro-4-(1-piperidinylmethyl)phenyl]-4-(1-
     pyrrolidinylmethyl)- (9CI)
MF   C22 H34 N4 O2
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L20  39 ANSWERS   REGISTRY  COPYRIGHT 2006 ACS on STN
IN   4-Piperidinol, 1-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-
     piperidinyl]methyl]- (9CI)
MF   C22 H35 N3 O
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L20  39 ANSWERS   REGISTRY  COPYRIGHT 2006 ACS on STN
```

IN Morpholine, 4-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI)
MF C21 H32 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Thiomorpholine, 4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI)
MF C21 H33 N3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 4-Piperidinol, 1-[[3-nitro-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI)
MF C22 H34 N4 O3

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Piperidine, 4-(1-piperidinylmethyl)-1-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI)
MF C22 H35 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Piperidine, 1-[4-(1-piperidinylmethyl)-3-(trifluoromethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI)
MF C23 H34 F3 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Morpholine, 4-[[1-[4-(1-pyrrolidinylmethyl)phenyl]-4-piperidinyl]methyl]- (9CI)
MF C21 H33 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Piperazine, 1-(1-methylethyl)-4-[[3-methyl-4-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI)
MF C25 H42 N4





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Thiomorpholine, 4-[[3-[4-(1-pyrrolidinylmethyl)-1-piperidinyl]phenyl]methyl]- (9CI)
MF C21 H33 N3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 39 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Piperidine, 1-[2-methyl-4-(1-pyrrolidinylmethyl)phenyl]-4-(1-pyrrolidinylmethyl)- (9CI)
MF C22 H35 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL